A French pine bark extract lowered a key bone-breakdown marker in women with weakened bones, and it also eased their pain. That is the headline from two new companion papers from the University of Würzburg. The fine print matters a lot, though, and it changes how you should read the result.
What the researchers actually tested
The supplement was Pycnogenol®, a standardized extract of French maritime pine bark known for antioxidant and anti-inflammatory properties. Until now, nobody had tested its effect on bone turnover in humans.
The study (Part I, Frontiers in Nutrition, 2026) was a randomized, double-blind, placebo-controlled trial in 67 women with osteopenia or clinically stable osteoporosis. This is the "pre-therapeutic" stage, where a person has bone loss but is not necessarily on standard antiresorptive drugs.
- Pycnogenol group: 33 women, 100 mg twice daily (200 mg/day)
- Placebo group: 34 women
- Phase 1 (3 months): placebo-controlled
- Phase 2 (3 months): an open extension in which everyone took Pycnogenol
The primary endpoints were blood markers of bone resorption (CTX-1) and bone formation (P1NP).
The striking finding: a bone-breakdown marker dropped
In the Pycnogenol group, serum CTX-1, a marker of bone resorption, fell significantly versus baseline after 3 months (p = 0.0327) and after 6 months (p = 0.0227). A second resorption marker, NTX-1, also dropped from baseline at the end of the extension (p = 0.0100).
The researchers also measured a gut-derived metabolite of pine bark compounds, called M1, in saliva. Levels were higher in the Pycnogenol group than in the placebo group after 3 months (p = 0.0289). Across 131 samples, M1 had a weak inverse association with CTX-1 (r = -0.216, p = 0.013). Lab experiments with human mesenchymal stromal cells also suggested that Pycnogenol components enhanced bone-forming (osteogenic) differentiation in vitro.
The catch: no difference versus placebo
The study found no between-group differences in CTX-1 at any visit. The drop appeared within the Pycnogenol group compared with its own baseline, and the placebo group was not significantly different from it. Within-group changes are weaker evidence than a clear win over placebo. Part of the change could reflect natural variation or other factors.
Bone formation (P1NP) did not change significantly. So the data hint at less bone breakdown, not more bone building. The authors themselves call the findings a potential protective effect.
The bonus: less pain, more vitality
The companion paper (Part II) looked at quality of life and safety in the same 67 women.
- Bodily pain (SF-36v2): improved with Pycnogenol and stayed flat with placebo. The effect held after adjusting for baseline (p = 0.0106).
- Vitality: a similar advantage for Pycnogenol (p = 0.0282).
- QUALEFFO-41 total score (an osteoporosis-specific questionnaire): no difference between groups.
- QUALEFFO-41 pain domain: after 6 months, scores were lower in women who took Pycnogenol continuously than in those switched from placebo (p = 0.0231).
So the quality-of-life signal is real but patchy. It showed up on some questionnaires and not others.
Safety snapshot
Over the study, the picture was reassuring:
- Blood count, kidney function (GFR, urea) and inflammation (CRP) showed no significant changes.
- Liver enzymes AST and ALT stayed stable.
- GGT, another liver-related enzyme, showed a small but significant decrease in the switched-over group (p = 0.0141).
- Serum phosphate declined but stayed within the reference range, reaching significance at 6 months (p = 0.0039). Nobody should ignore a mineral-metabolism shift, so it is worth tracking in longer trials.
Practical takeaways
Dose used in the trial: 100 mg Pycnogenol® twice daily, 200 mg total per day. The papers do not report any meal-timing instructions, so there is no evidence-based "best time" to take it.
Duration studied: 3 months against placebo, plus 3 months of open-label use. There is no data here beyond 6 months.
Who it might be relevant for: women with osteopenia or clinically stable osteoporosis who are in the pre-therapeutic stage, which is the group studied. Even then, treat it as exploratory.
Who should be cautious or skip it:
- Anyone expecting it to replace prescribed osteoporosis drugs. The authors position antiresorptives as the standard of care, and this trial tested a supplement as a possible add-on, not a substitute.
- Men, younger people and women with unstable or severe disease, who weren't the focus of this research.
- People with liver, kidney or mineral-metabolism issues, or those on medications. The papers don't address interactions, so check with a doctor first.
Limitations you should know
- Small sample of 67 women and a short duration of 6 months in total.
- Surrogate endpoints. Bone turnover markers are not fractures or bone mineral density, and neither paper reports those outcomes.
- No between-group CTX-1 difference and no change in P1NP.
- Open-label extension. Everyone took Pycnogenol in months 4 to 6, so those results lack a placebo comparison.
- Many secondary outcomes with modest p-values, which calls for cautious interpretation.
- The M1 correlation is weak, and in vitro cell work doesn't prove the same effect in the body.
The authors declared no commercial or financial conflicts of interest, and the trial is registered (DRKS00026630).
Bottom line
This trial is a promising first look, not proof. Pine bark extract was associated with lower bone-resorption markers, less pain and better vitality, with a clean short-term safety profile. Whether that translates into stronger bones or fewer fractures is the question that larger, longer trials with density and fracture endpoints will need to answer.
